Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q3 2024 Earnings Presentation
9 slides from Phibro Animal Health's earnings presentation, May 9, 2024
Slide 1: Phibro Animal Health Corporation Webcast and Conference Call
Phibro Animal Health Corporation Webcast and Conference Call May 9, 2024 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2024 Third Quarter Ended March 31, 2024 May 9, 2024 Webcast and Conference Call
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to future debt and leverage levels. All statements other than statements of historical or current
Slide 3: Key Themes
Key Themes To Acquire Zoetis’ MFA Continued Sales Strong Growth in Guidance affirmed and Certain Water Momentum Animal Health for adjusted Soluble Products • To Acquisition of Zoetis MFA Affirming fiscal year Q3 Total Consolidated sales and Q3 Animal Health sales and and certain water soluble 2024 g
Slide 4: Financial Performance - Consolidated
Financial Performance - Consolidated Third Quarter, Year-on-Year comparison $ in millions, except per share data Q3 Q3 YOY FY23 FY24 %∆ Consolidated Net Sales $ 245.7 $ 263.2 7% Net Income $ 10.0 $ 8.4 (16%) Diluted EPS $ 0.25 $ 0.21 (16%) Adjusted EBITDA $ 27.4 $ 29.7 9% Adjusted Net Income $ 11.6
Slide 5: Financial Performance – Animal Health
Financial Performance – Animal Health Third Quarter, Year-on-Year comparison $ in millions Q3 Q3 YOY FY23 FY24 %∆ Animal Health Net Sales $ 164.4 $ 181.3 10% MFAs & other 93.2 108.2 16% Nutritional specialties 45.0 40.2 (11%) Vaccines 26.2 32.9 26% Adj. EBITDA $ 34.2 $ 36.5 7% Adj. EBITDA Margin 20.
Slide 6: Financial Performance – Other Segments
Financial Performance – Other Segments Third Quarter, Year-on-Year comparison $ in millions Q3 Q3 YOY FY23 FY24 %∆ Mineral Nutrition Net Sales $ 62.9 $ 64.2 2% Adj. EBITDA $ 3.9 $ 4.7 21% Adj. EBITDA Margin 6.1% 7.3% +120 bps Performance Products Net Sales $ 18.3 $ 17.7 (4%) Adj. EBITDA $ 2.4 $ 2.4
Slide 7: Key Capitalization Metrics
Key Capitalization Metrics March 31, 2024 Free cash flow was $40+ million for the TTM -- positive cash from operating activities of $79 million, less capital expenditures of $(39) million. Free Cash Flow (1) Cash and cash equivalents and short-term investments of $99 million 4.4x gross leverage rati
Slide 8: Financial Guidance
Financial Guidance Fiscal Year 2024 $ in millions, except earnings per share (EPS) data FY 2023 FY 2024 Full Year Guidance Actual Low High Consolidated Net Sales $ 978 $ 980 $ 1,020 Net Income $ 33 $ 7 $ 12 Diluted EPS $ 0.81 $ 0.17 $ 0.30 Adjusted EBITDA $ 113 $ 106 $ 112 Adjusted Net Income $ 49 $
Slide 9: Q&A
PAHC Company Overview Q&A 9 May 9, 2024 Webcast and Conference Call